News
SAVA
--
0.00%
--
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
Cassava said Wednesday that patients who received its experimental Alzheimer's drug showed improved cognition at a year. But SAVA stock dipped.
Investor's Business Daily · 49m ago
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once-highflying SAVA stock has plummeted this year.
Investor's Business Daily · 4h ago
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
Benzinga · 5h ago
Cassava Sciences Announces Top-Line Results Of 12-month Interim Analysis From Open-Label Study Evaluating Simufilam In Alzheimer's Disease; Says Cognition Scores Improved 3.2 Points On ADAS-Cog, Baseline To Month 12
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12 No Behavior Disorders on NPI in
Benzinga · 8h ago
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12No Behavior Disorders on NPI in Over 50% Of Study Subjects at Month 12Initiation of P...
GlobeNewswire · 8h ago
Cassava Sciences Says Open-Label Trial of Simufilam Shows Improved Cognition Scores in Alzheimer's Disease Patients
MT Newswires · 10h ago
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - September 21, 2021) -  Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who...
Newsfile Corp · 1d ago
Cassava Deadline Alert
New York, New York--(Newsfile Corp. - September 20, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of...
Newsfile Corp · 1d ago
Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know
Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.
Zacks · 1d ago
It’s Best to Stick to the Fundamentals With Skillz Stock
Investor Place · 2d ago
Cassava Shareholder Notice
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 18, 2021) - Faruqi & Faruqi, LLP, a lea...
Newsfile · 4d ago
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
Investor Place · 5d ago
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
Zacks.com · 5d ago
Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. (SAVA) of Approaching Lead Plaintiff Deadline
Boston, Massachusetts--(Newsfile Corp. - September 14, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug d...
Newsfile Corp · 09/14 16:29
Cassava CEO Remi Barbier defends Alzheimer's drug simufilam, responds to petition
Cassava Sciences (NASDAQ:SAVA) CEO Remi Barbier defended the Alzheimer's drug simulfilam against allegations presented in a citizen petition, saying the company has never claimed the drug has efficacy. "If you
Seekingalpha · 09/13 13:06
Webull provides a variety of real-time SAVA stock news. You can receive the latest news about Cassava Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.